

## One Retinoblastoma World: Reaching Every Child

By Dr. Brenda Gallie, MD  
Senior Scientist Head of Health Informatics Research  
Head of Retinoblastoma Program, Sick Kids

November 26, 2015  
5:00 pm - 6:00 pm  
100 College St, Banting Institute, Room 131

Retinoblastoma, a rare eye cancer in children, has revealed the essential genetic basis of cancer and delivered personalized medicine for families, where awareness and resources have achieved 98% survival. To address the 70% of children with retinoblastoma who still die, *One Retinoblastoma World* has emerged with innovative partnerships and technologies, iteratively advancing evidence-based care from the bedside to make retinoblastoma a “Zero Death” cancer.

### BIOGRAPHY



Dr. Gallie’s research teams focused on optimizing of many aspects of care for retinoblastoma. They delineated *RB1* gene mechanisms and progressive genetic changes in this cancer, discovered an oncogene-driven form of the disease, and developed molecular diagnostics with a business model keeping the patient foremost. Now Dr. Gallie’s focus within One Retinoblastoma World is innovative partnerships and technologies mapping all treatment centres ([1rbw.org](http://1rbw.org)), establishing universal staging and guidelines and collecting point-of-care summary data on every child, in order to set the stage for a global learning health system.